BridgeBio have substantially boosted its progress of a innovative therapy for amyloid heart disease, leveraging the investigational drug. Preliminary clinical information reveals potential improvements for patients suffering from the serious condition. This focus underscores the company’s dedication to managing significant medical demands in this